trial · primary record
Ruxolitinib
T-cell Lymphoma
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 44 |
| Primary completion | 2027-10-31 |
| Primary endpoint | Cumulative Incidence (CI) of relapse |
| Registry ID | NCT07356245 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:31:49.619Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07356245
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.